A medical journal criticized British drugmaker GlaxoSmithKline on Thursday for delaying access to key data from a trial of its antidepressant Seroxat that would have shown earlier that it is neither safe or effective in adolescents. The widely used medicine, known generically as paroxetine, is linked to an increased risk of suicide in young people and has carried a Food and Drug Administration "black box warning" advising against its use in adolescents since 2004.